Cargando…

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study

Background: In a 24-week, Phase 3 study (PAOLA), long-acting pasireotide demonstrated superior efficacy (GH <2.5 µg/L and IGF-1 <ULN) over continued treatment with long-acting octreotide/lanreotide in pts with uncontrolled acromegaly (Gadelha MR, et al. Lancet Diabetes Endocrinol. 2014;2:875-8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadelha, Mônica, Colao, Annamaria, Bex, Marie, Campigotto, Federico, Bartalotta, Amy, Maamari, Ricardo, Raverot, Gérald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552256/ http://dx.doi.org/10.1210/js.2019-SAT-433

Ejemplares similares

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SAT-257 Coexisting Craniopharyngioma and Acromegaly
por: Yang, Almira, et al.
Publicado: (2020)

SAT-305 Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide
por: Dasgupta, Pooja, et al.
Publicado: (2020)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

SAT-267 Pregnancy in Acromegaly: Report of Five Cases
por: Burcea, Iulia Florentina, et al.
Publicado: (2020)

SAT-249 Polyarticular Osteoarthritis: A Disabling Manifestation of Acromegaly
por: Khan, Azkia, et al.
Publicado: (2020)

SAT-251 New Diagnosis of Acromegaly with DKA as Initial Presentation
por: Gundluru, Rajani, et al.
Publicado: (2020)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

SAT-473 Acromegaly and Drug-Induced Parkinsonism Were Controlled by Lanreotide
por: Iwabuchi, Masayasu
Publicado: (2019)

SAT-LB48 Novel Genetic Variant of Carney Complex With Acromegaly
por: Cristiano, Elizabeth, et al.
Publicado: (2020)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial
por: Gadelha, Mônica, et al.
Publicado: (2023)

SAT-471 Abnormal Thyroid Function Tests in Acromegaly: A Clinical Conundrum
por: Fernandes, Stuti, et al.
Publicado: (2019)

SAT-470 A Case of Acromegaly with Concomitant Hypercortisolism Presenting with Diabetic Ketoacidosis
por: Gonzales, Irish Judy
Publicado: (2019)

SAT-472 Increased Thyroid Cancer Risk in Acromegaly: A Report of 3 Cases
por: Jaisinghani, Priya, et al.
Publicado: (2019)

SAT-LB078 Acromegaly Disease Activity According to ACRODAT® in Spain: ACROVAL Study
por: Marazuela, Monica, et al.
Publicado: (2019)

SAT605 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

SAT-436 Adjuvant Therapeutic Modalities in Acromegaly: Clinical Course and Factors Predicting Biochemical Controls
por: Jung, Hyein, et al.
Publicado: (2019)

SAT-469 Empty Sella Making Big Changes: A Case of Acromegaly and Empty Sella Syndrome
por: Padniewski, Jessica, et al.
Publicado: (2019)

SAT-466 Cases of Acromegaly and Presumed Prolactinoma in Setting of Empty Sella Syndrome: Presentation and Management Implications
por: Uwaifo, Gabriel
Publicado: (2019)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database
por: Kelepouris, Nicky, et al.
Publicado: (2019)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

SAT-259 Acromegaly by Pituitary Adenoma Associated with ACTH-Independent Cushing Syndrome by Adrenal Carcinoma: Case Report
por: Minuzzi, Ricardo Kunde, et al.
Publicado: (2020)

SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
por: Geer, Eliza Brevoort, et al.
Publicado: (2023)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

SAT-431 Parameters of Glucose Metabolism Independently Predict Post Glucose Load Growth Hormone Concentrations in Patients with Acromegaly
por: Micko, Alexander, et al.
Publicado: (2019)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_30v4m2b1q2sk2tj08u9beakj1d